Kappa Bioscience, a supplier of vitamin K2 under the brand K2Vital, announced the formation of a “blue ribbon” scientific and medical advisory board to support and expand the scientific knowledge base for vitamin K2.
 
The board’s primary aim is to grow awareness of the rapidly-expanding range of benefits associated with vitamin K2 in the form of menaquinone 7 (MK-7). It will include authorities in the fields of cardiology, immunology, kinesiology, and molecular nutrition, aiming to set a standard for scientific support and advancement of emerging nutritional compounds.
 
Members
The current composition of the advisory board includes:
 
Dr. John Ivy, the Teresa Lozano Long Endowed chair emeritus at the University of Texas at Austin. He received his PhD in exercise physiology from the University of Maryland and trained in physiology and metabolism at Washington University School of Medicine as an NIH post-doctoral fellow. His research interests include the effect of exercise and nutritional supplementation on physical performance and wellness;
 
Dr. Susanne Talcott, associate professor Texas A&M University, Food Science & Technology​, and a molecular researcher. Her research focuses on translational pharmacokinetics and pharmacodynamics of food compounds and their physiological metabolites related to inflammation, cancer prevention, and intestinal health with a focus on human clinical trials;
 
Dr. Nathan Wong, cardiovascular epidemiologist, a specialist in preventive cardiology, and professor and director, of the Heart Disease Prevention Program, Division of Cardiology at the University of California. He received his Ph.D. degrees in epidemiology from Yale University and his research focuses on the epidemiology of diabetes and cardiovascular disease, subclinical atherosclerosis, and dyslipidemia.
 
Additional members will be announced in the immediate future, according to Kappa Bioscience.
 
“The formation of Kappa’s scientific and medical advisory board is a further demonstration of the company’s commitment to maintaining its leadership position in the K2 sector and to bringing its remarkable health benefits to a growing number of consumers worldwide,” Egil Greve, Kappa’s CEO, said. “We are honored to have attracted this esteemed group of scientists. The top-class experts together have authored over 700 scientific papers. We are confident that with their help, awareness of vitamin K2 and its scope of benefits will rapidly accelerate.”
 
The group will be led by Trygve Bergeland, PhD, vice president of science at Kappa Bioscience, who will coordinate their activities with the company’s current research initiatives already underway.
 
“The addition of this unique group of scientists to our highly qualified internal science team dramatically expands the scope of scientific support possible for Kappa’s platform ingredient,” Bergeland said. “Together, we believe that we will be able to establish a recommended daily intake for K2 for all people as an essential nutrient, as well as raising awareness of its role in maintaining health.”
 
“Kappa Bioscience has always been a forerunner in the K2 market. With the formation of the advisory board, we are taking another meaningful step to explore the many potential health effects of this stunning vitamin and share it with our customers and the world,” Dominik Mattern, VP of Marketing, said.